Global Graves Diseases Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Graves Diseases treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Apitope International NV, AV7 Ltd , Immunovant Sciences Ltd, Novartis AG, Omeros Corp and others.
A Significant contribution to the Graves Diseases pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Graves Diseases pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Graves Diseases condition and increased access to investments is encouraging growth of Graves Diseases drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Graves Diseases drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Graves Diseases therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Graves Diseases pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Graves Diseases. Further, orphan drug status, fast track designation, grants awarded and other special status for Graves Diseases pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Graves Diseases pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Graves Diseases Pipeline candidates-
A Significant contribution to the Graves Diseases pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Graves Diseases pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Graves Diseases condition and increased access to investments is encouraging growth of Graves Diseases drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Graves Diseases drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Graves Diseases therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Graves Diseases pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Graves Diseases. Further, orphan drug status, fast track designation, grants awarded and other special status for Graves Diseases pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Graves Diseases pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Graves Diseases Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Graves Diseases drugs
- Late phase: Phase 3 and in-approval Graves Diseases drugs
- Company overview
- Snapshot
- Graves Diseases therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Graves Diseases- Disease Overview
2.2 Graves Diseases- Pipeline Snapshot
2.3 Graves Diseases- Pipeline Drugs by Phase
2.4 Graves Diseases- Pipeline Drugs by Company
2.5 Graves Diseases- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Apitope International NV Graves Diseases Drug Pipeline, H2- 2019
3.2 AV7 Ltd Graves Diseases Drug Pipeline, H2- 2019
3.3 Immunovant Sciences Ltd Graves Diseases Drug Pipeline, H2- 2019
3.4 Novartis AG Graves Diseases Drug Pipeline, H2- 2019
3.5 Omeros Corp Graves Diseases Drug Pipeline, H2- 2019
3.6 Rodos BioTarget Graves Diseases Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Graves Diseases- Phase 1 Drug Details
4.2 Graves Diseases- Phase 1 Drug Overview
4.3 Graves Diseases- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Graves Diseases- Phase 2 Drug Details
5.2 Graves Diseases- Phase 2 Drug Overview
5.3 Graves Diseases- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Graves Diseases- Phase 3 Drug Details
6.2 Graves Diseases- Phase 3 Drug Overview
6.3 Graves Diseases- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Graves Diseases- Pre-clinical Phase Drug Details
7.2 Graves Diseases- Pre-clinical Phase Drug Overview
7.3 Graves Diseases- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Graves Diseases- Disease Overview
2.2 Graves Diseases- Pipeline Snapshot
2.3 Graves Diseases- Pipeline Drugs by Phase
2.4 Graves Diseases- Pipeline Drugs by Company
2.5 Graves Diseases- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Apitope International NV Graves Diseases Drug Pipeline, H2- 2019
3.2 AV7 Ltd Graves Diseases Drug Pipeline, H2- 2019
3.3 Immunovant Sciences Ltd Graves Diseases Drug Pipeline, H2- 2019
3.4 Novartis AG Graves Diseases Drug Pipeline, H2- 2019
3.5 Omeros Corp Graves Diseases Drug Pipeline, H2- 2019
3.6 Rodos BioTarget Graves Diseases Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Graves Diseases- Phase 1 Drug Details
4.2 Graves Diseases- Phase 1 Drug Overview
4.3 Graves Diseases- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Graves Diseases- Phase 2 Drug Details
5.2 Graves Diseases- Phase 2 Drug Overview
5.3 Graves Diseases- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Graves Diseases- Phase 3 Drug Details
6.2 Graves Diseases- Phase 3 Drug Overview
6.3 Graves Diseases- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Graves Diseases- Pre-clinical Phase Drug Details
7.2 Graves Diseases- Pre-clinical Phase Drug Overview
7.3 Graves Diseases- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
